Molecular typing is predicated on molecular genetic testing and is not yet routinely out there. Molecular subtypes and immunohistochemical surrogate markers of the tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-sixty seven https://allana874qzf0.wikifordummies.com/user